General Information of Drug (ID: DMAHGKE)

Drug Name
E7016 Drug Info
Synonyms
UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; E7016; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [1]
Cross-matching ID
PubChem CID
11660296
CAS Number
CAS 902128-92-1
TTD Drug ID
DMAHGKE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Olaparib DM8QB1D Ovarian cancer 2C73 Approved [3]
Rucaparib DM9PVX8 Ovarian cancer 2C73 Approved [4]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [5]
MK-4827 DMLYGH4 Ovarian cancer 2C73 Phase 3 [2]
BSI-201 DMM0VO3 Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Rubraca rucaparib DM25TMP Ovarian cancer 2C73 Phase 3 [7]
ABT-888 DM4HYMS Breast cancer 2C60-2C65 Phase 3 [2]
INO-1001 DM5L8QT Brain cancer 2A00 Phase 3 [8]
BGP-15 DMYDM68 Type-2 diabetes 5A11 Phase 2 [9]
BGB-290 DMRO6XT Ovarian cancer 2C73 Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT01605162) Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma. U.S. National Institutes of Health.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
9 BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.